Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference


Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 14, 2024 beginning at 10:40 a.m. Eastern Time.

A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient's own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X.


These press releases may also interest you

at 10:23
SREE CHAGUTURU, MD, CHIEF MEDICAL OFFICER, CVS HEALTH, BECOMES CHAIR OF THE AMERICAN TELEMEDICINE ASSOCIATION BOARD OF DIRECTORS
The American Telemedicine Association (ATA) today announced that Sree Chaguturu, MD, has become Chair of the Board of Directors. Dr. Chaguturu is Executive Vice President and Chief Medical Officer, CVS Health®, where he leads the enterprise medical...

at 10:10
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health,...

at 10:00
RevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board
RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today the appointment of Dr. Emmett Cunningham to its Strategic Advisory Board (SAB) and as a private investor. Dr....

at 10:00
Boehringer Ingelheim Unveils New R&D Laboratory in St. Joseph, Mo., Pioneering the Future of Animal Health Products
Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo. location by hosting a ribbon cutting. This state-of-the-art facility is set to revolutionize the development of future...

at 10:00
Services PMI® at 49.4%; April 2024 Services ISM® Report On Business®
Economic activity in the services sector contracted in April for the first time since December 2022, ending a period of 15 consecutive months of growth, say the nation's purchasing and supply executives in the latest Services ISM® Report On...

at 09:40
Global RNAi Therapeutics Market Insights & Forecasts with Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering. The global RNAi therapeutics...

More news about Health...


News published on and distributed by: